文献速递主动脉疾病

PYTHAGORAS美国临床试验:Aorfix内移植物治疗极度成角主动脉瘤颈的五年结局

Five-year outcomes of the PYTHAGORAS U.S. clinical trial of the Aorfix endograft for endovascular aneurysm repair in patients with highly angulated aortic necks.
PubMed 文献 · J Vasc Surg · 2017-02-09

PYTHAGORAS美国试验纳入218例肾下腹主动脉瘤患者,按近端瘤颈角度分为标准角组(<60°,67例)和高度成角组(≥60°,151例),评估Aorfix内移植物行EVAR的5年结局。5年随访显示两组在I/III型内漏、移植物移位、瘤囊扩张及全因死亡、动脉瘤相关死亡、破裂和再干预率上均无显著差异,支持该移植物在高度成角瘤颈中的“标签内”应用。

要点

  • 高度成角组(≥60°)5年瘤囊扩张率15.0%,标准角组4%,但差异无统计学意义。
  • 两组5年无I型或III型内漏,移植物移位率分别为3%和4%。
  • 5年无全因死亡率为69%,无动脉瘤相关死亡率为96%,无破裂率为99%。

核心结论

  • Aorfix内移植物在高度成角(≥60°)肾下主动脉瘤颈患者中5年结局与标准角组相当,支持其标签内使用。

研究设计与样本

  • 前瞻性多中心美国临床试验(PYTHAGORAS),纳入218例患者,标准角组67例,高度成角组151例,随访至5年。

主要发现

  • 5年时87%存活患者完成随访,两组均无I型或III型内漏。
  • 移植物移位率标准角组4% vs 高度成角组3%,瘤囊扩张率4% vs 15.0%(P≥.27)。
  • 5年无全因死亡69%(73% vs 68%,P=.43),无动脉瘤相关死亡96%(99% vs 95%,P=.44)。
  • 5年无动脉瘤破裂99%(99% vs 99%,P=1.0),无器械相关二次干预83%(88% vs 80%,P=.18)。

临床怎么用

  • 对于近端瘤颈角度≥60°的肾下腹主动脉瘤患者,可考虑使用Aorfix内移植物行EVAR。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Early and midterm outcomes of the Prospective Aneurysm Trial: High Angle Aorfix Bifurcated Stent Graft (PYTHAGORAS) trial in patients with highly angulated aortic necks (≥60 degrees) have already been published and shown comparable outcomes to other endografts in normal anatomy. Herein, we present the long-term outcomes of the PYTHAGORAS trial of Aorfix (Lombard Medical, Irvine, Calif) for patients with highly angulated aortic neck anatomy. METHODS: The Aorfix endograft is a highly conformable nitinol/polyester device designed for transrenal fixation. The U.S. trial enrolled 218 patients and observed all patients at 1 month, 6 months, and 12 months and then annually for a total of 5 years. Endovascular aneurysm repair (EVAR)-specific complications were compared between the standard-angle (<60 degrees) and highly angulated (≥60 degrees) neck groups at 5 years using standard statistical methods. Kaplan-Meier analysis was performed to evaluate the overall 5-year survival and freedom from aneurysm rupture, aneurysm-related mortality, and reintervention. RESULTS: Of the 218 patients enrolled in the trial, there were 67 patients in the standard-angle neck group (I) and 151 patients in the highly angulated neck group (II). Mean proximal neck angle was 45 degrees in group I vs 83 degrees in group II (P < .001). At 5 years, 87% of surviving patients were followed up. The 5-year EVAR-specific results showed no type I or type III endoleak in either group, 4% migration in group I vs 3% in group II, and 4% sac expansion in group I vs 15.0% in group II (P ≥ .27). The 5-year freedom from all-cause mortality was 69% (73% in group I vs 68% in group II; P = .43); from aneurysm-related mortality, 96% (99% vs 95%; P = .44); from aneurysm rupture, 99% (99% vs 99%; P = 1.0); and from device-related secondary intervention, 83% (88% vs 80%; P = .18). None of these differed between groups. CONCLUSIONS: The U.S. PYTHAGORAS trial of the Aorfix endograft is the first EVAR clinical trial to include a majority of highly angulated (≥60 degrees) infrarenal aortic necks and is the first to produce evidence after 5 years of implantation. Despite predictors of worse short- and long-term outcomes, pertinent outcomes were better than or similar to those of trials with less severe anatomy. These results support the use of this "on-label" endovascular option, particularly in patients with highly angulated aortic neck anatomy.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Malas MB, Hicks CW, Jordan WD, et al. Five-year outcomes of the PYTHAGORAS U.S. clinical trial of the Aorfix endograft for endovascular aneurysm repair in patients with highly angulated aortic necks. J Vasc Surg. 2017. PMID: 28190716. doi:10.1016/j.jvs.2016.10.120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。